Company Profile
Gilead Sciences Stock Price, News & Catalysts
- Ticker:
- GILD
- Exchange:
- NASDAQ
- Sector:
- Infectious Disease, Biopharma, Nucleic Acid Drugs, CAR-T Therapy, Gene Therapy
- Location:
- United States
Stock performance
144.23 USD (-0.28%)
Close
Last updated: October 6, 2026
158B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, GILD closed down 0.28% at $144.23. No new same-company headline was identified in the current news window.
Company overview
Virology-Centered Biopharmaceutical Company
Gilead Sciences is a global biopharmaceutical company with core businesses in HIV, viral hepatitis, oncology, and inflammation. The company operates in more than 35 countries and combines internally developed antiviral expertise with acquired capabilities in antibody-drug conjugates, cell therapy, T-cell engagers, and targeted immunology.
HIV Treatment and Prevention
HIV is Gilead's largest franchise and includes Biktarvy and Descovy for oral treatment and prevention, as well as lenacapavir-based long-acting options. Yeztugo extends lenacapavir into HIV prevention, while the partnership with Merck combines lenacapavir with islatravir as a potential first once-weekly oral HIV treatment regimen.
Liver Disease Portfolio
Gilead has long-standing franchises in hepatitis B and C and is expanding in hepatitis delta and primary biliary cholangitis. Hepcludex is the first FDA-approved treatment for chronic hepatitis delta virus infection in the United States, while Livdelzi addresses primary biliary cholangitis and is being studied across broader disease populations.
Oncology and Cell Therapy
The oncology portfolio includes Trodelvy, a TROP2-directed antibody-drug conjugate, and the Yescarta and Tecartus CAR T-cell therapies. The acquisition of Arcellx added anitocabtagene autoleucel for multiple myeloma, while Tubulis added next-generation antibody-drug conjugates and a platform for developing additional targeted oncology products.
Inflammation and Immune Modulation
Gilead is building an inflammation portfolio through internally developed medicines and acquisitions. Livdelzi provides an initial commercial base, and the acquisition of Ouro Medicines added gamgertamig, a BCMAxCD3 T-cell engager being developed for autoimmune disease. The company is also exploring how oncology-derived immune-cell technologies can be applied to chronic immune disorders.
Multi-Modal Research Platform
Gilead's development capabilities now span small-molecule antivirals, long-acting formulations, antibody-drug conjugates, autologous cell therapy, and bispecific T-cell engagers. This broader platform supports diversification beyond HIV while preserving the company's established expertise in infectious disease and global access programs.
Future catalysts
- FDA PDUFA decision on the once-weekly oral formulation of Yeztugo for HIV pre-exposure prophylaxis on February 2, 2027.
- European Commission decision on Trodelvy plus Keytruda for first-line PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer following a positive CHMP opinion.
- Planned regulatory submissions for once-weekly oral islatravir/lenacapavir HIV treatment following positive Phase 3 ISLEND-1 and ISLEND-2 results.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Gilead Sciences (GILD)?
Gilead Sciences (GILD) most recently closed at 144.23 USD, a -0.28% move versus the previous session.
What is the market cap of Gilead Sciences (GILD)?
Gilead Sciences currently has a market capitalization of 158B USD on BioPharmSignal.
What does Gilead Sciences do?
Virology-Centered Biopharmaceutical Company Gilead Sciences is a global biopharmaceutical company with core businesses in HIV, viral hepatitis, oncology, and inflammation. The company operates in more than 35 countries and combines internally developed antiviral expertise with acquired capabilities in antibody-drug conjugates, cell therapy, T-cell engagers,...
On which exchange is GILD stock listed?
Gilead Sciences (GILD) is associated with NASDAQ, United States, Infectious Disease, Biopharma, Nucleic Acid Drugs, CAR-T Therapy, Gene Therapy.
What is PD-L1?
European Commission decision on Trodelvy plus Keytruda for first-line PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer following a positive CHMP opinion.
Which conditions is Gilead Sciences targeting with PD-L1?
Gilead Sciences is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Gilead Sciences describe recent progress with PD-L1?
European Commission decision on Trodelvy plus Keytruda for first-line PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer following a positive CHMP opinion.
What is ISLEND-1?
Planned regulatory submissions for once-weekly oral islatravir/lenacapavir HIV treatment following positive Phase 3 ISLEND-1 and ISLEND-2 results.